Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain
- 1 July 2001
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 133 (6) , 875-885
- https://doi.org/10.1038/sj.bjp.0704142
Abstract
Clinical studies have shown enhancement of cyclosporine toxicity when co-administered with the immunosuppressant sirolimus. We evaluated the biochemical mechanisms underlying the sirolimus/cyclosporine interaction on rat brain metabolism using magnetic resonance spectroscopy (MRS) and compared the effects of sirolimus with those of the structurally related RAD. Two-week-old rats (25 g) were allocated to the following treatment groups (all n=6): I. control, II. cyclosporine (10 mg kg(-1) d(-1)), III. sirolimus (3 mg kg(-1) d(-1)), IV. RAD (3 mg kg(-1) d(-1)), V. cyclosporine+sirolimus and VI. cyclosporine+RAD. Drugs were administered by oral gavage for 6 days. Twelve hours after the last dose, metabolic changes were assessed in brain tissue extracts using multinuclear MRS. Cyclosporine significantly inhibited mitochondrial glucose metabolism (glutamate: 78+/-6% of control; GABA: 67+/-12%; NAD(+): 76+/-3%; P<0.05), but increased lactate production. Sirolimus and RAD inhibited cytosolic glucose metabolism via lactate production (sirolimus: 81+/-3% of control, RAD: 69+/-2%; P<0.02). Sirolimus enhanced cyclosporine-induced inhibition of mitochondrial glucose metabolism (glutamate: 60+/-4%; GABA: 59+/-8%; NAD(+): 45+/-5%; P<0.02 versus cyclosporine alone). Lactate production was significantly reduced. In contrast, RAD antagonized the effects of cyclosporine (glutamate, GABA, and NAD(+), not significantly different from controls). The results can partially be explained by pharmacokinetic interactions: co-administration increased the distribution of cyclosporine and sirolimus into brain tissue, while co-administration with RAD decreased cyclosporine brain tissue concentrations. In addition RAD, but not sirolimus, distributed into brain mitochondria. The combination of cyclosporine/RAD compares favourably to cyclosporine/sirolimus in regards to their effects on brain high-energy metabolism and tissue distribution in the rat.Keywords
This publication has 42 references indexed in Scilit:
- Evaluation of the effects of immunosuppressants on neuronal and glial cells in vitro by multinuclear magnetic resonance spectroscopyBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1996
- EFFECTS OF THE PHARMACOKINETIC INTERACTION BETWEEN ORALLY ADMINISTERED SIROLIMUS AND CYCLOSPORINE ON THE SYNERGISTIC PROLONGATION OF HEART ALLOGRAFT SURVIVAL IN RATS1Transplantation, 1996
- SYNERGISTIC EFFECTS OF CYCLOSPORINE AND RAPAMYCIN IN A CHRONIC NEPHROTOXICITY MODEL1Transplantation, 1996
- CYCLOSPORINE NEPHROTOXICITY: ATTENUATION BY AN ANTIOXIDANT-INHIBITOR OF LIPID PEROXIDATION IN VITRO AND IN VIVOTransplantation, 1994
- CyclosporinDrugs, 1993
- Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?Annals of Neurology, 1992
- Effect of cyclosporine on oxidative phosphorylation and adenylate energy charge of regenerating rat liverZeitschrift für Die Gesamte Experimentelle Medizin, 1989
- Regulation of cellular energy metabolismThe Journal of Membrane Biology, 1982
- CYCLOSPORIN A INITIALLY AS THE ONLY IMMUNOSUPPRESSANT IN 34 RECIPIENTS OF CADAVERIC ORGANS: 32 KIDNEYS, 2 PANCREASES, AND 2 LIVERSThe Lancet, 1979
- Fine control of the conversion of pyruvate (phosphoenolpyruvate) to oxaloacetate in various speciesFEBS Letters, 1978